01 January 2018 | News
Hepatitis C is known as a silent epidemic and it has been reported that 2,000 new cases emerging every year in Malaysia
CCM Duopharma Biotech Berhad (CCMD) is a subsidiary of Chemical Company of Malaysia Berhad that has seven pharmaceutical units under its umbrella.
Company is engaged in the development, manufacturing and marketing of generic drugs and branded pharmaceutical products.
Hepatitis C is widely spreading in Malaysia and treatment is proved to be very expensive for common patient.
To improve access and affordability for patients, CCM Duopharma Biotech Bhd (CCMD) has entered into collaboration with Natco Pharma Ltd of India to commercialize a range of Hepatitis C products in Malaysia.
Under the strategic partnership, CCMD also gained the right from Natco Pharma Ltd to market and sell a wide-range of Hepatitis products in Malaysia.
According to Duopharma, these products were developed by Gilead Sciences Ireland UC and have allowed Natco Pharma Ltd the right to manufacture market and sell Active Pharmaceutical Ingredient and formulations containing their proprietary compound.